The logo for Kentucky BioProcessing LLC is displayed at the facility in Owensboro, Kentucky, on Aug. 5, 2014. ZMapp, developed by Mapp Biopharmaceutical Inc. and manufactured by Kentucky BioProcessing, has been used to treat the Ebola virus. (Luke Sharrett/Bloomberg via Getty Images)

MONROVIA, Liberia - Two African health workers who received doses of the experimental Ebola drug ZMapp are set to be discharged from the hospital later this week, a Liberian health official told ABC News today.

Ebola Wards See Flood of Patients, Outflow of Bodies

Looking for Hope in a Hot Zone

Three African health workers - two African doctors and one physician's assistant - received the drug after contracting the virus earlier this month, according to Dr. Moses Massaquoi, who heads Ebola case management at Liberia's health ministry.

Though they were all showing signs of improvement at first, one of the doctors died on Aug. 24. He also had diabetes and hypertension, Massaquoi said.

The remaining two patients improved soon after receiving the first of three doses of ZMapp - a cocktail of three antibodies meant to attack the virus. They are expected to be discharged on Friday.

Click here for more headlines from the Ebola outbreak.